Literature DB >> 24857696

Volumetric-modulated arc radiotherapy for pancreatic malignancies: dosimetric comparison with sliding-window intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy.

Nima Nabavizadeh1, Anna O Simeonova2, Joseph G Waller2, Jeanna L Romer2, Debra L Monaco2, David A Elliott2, James A Tanyi2, Martin Fuss2, Charles R Thomas2, John M Holland2.   

Abstract

Volumetric-modulated arc radiotherapy (VMAT) is an iteration of intensity-modulated radiotherapy (IMRT), both of which deliver highly conformal dose distributions. Studies have shown the superiority of VMAT and IMRT in comparison with 3-dimensional conformal radiotherapy (3D-CRT) in planning target volume (PTV) coverage and organs-at-risk (OARs) sparing. This is the first study examining the benefits of VMAT in pancreatic cancer for doses more than 55.8 Gy. A planning study comparing 3D-CRT, IMRT, and VMAT was performed in 20 patients with pancreatic cancer. Treatments were planned for a 25-fraction delivery of 45 Gy to a large field followed by a reduced-volume 8-fraction external beam boost to 59.4 Gy in total. OARs and PTV doses, conformality index (CI) deviations from 1.0, monitor units (MUs) delivered, and isodose volumes were compared. IMRT and VMAT CI deviations from 1.0 for the large-field and the boost plans were equivalent (large field: 0.032 and 0.046, respectively; boost: 0.042 and 0.037, respectively; p > 0.05 for all comparisons). Both IMRT and VMAT CI deviations from 1.0 were statistically superior to 3D-CRT (large field: 0.217, boost: 0.177; p < 0.05 for all comparisons). VMAT showed reduction of the mean dose to the boost PTV (VMAT: 61.4 Gy, IMRT: 62.4 Gy, and 3D-CRT: 62.3 Gy; p < 0.05). The mean number of MUs per fraction was significantly lower for VMAT for both the large-field and the boost plans. VMAT delivery time was less than 3 minutes compared with 8 minutes for IMRT. Although no statistically significant dose reduction to the OARs was identified when comparing VMAT with IMRT, VMAT showed a reduction in the volumes of the 100% isodose line for the large-field plans. Dose escalation to 59.4 Gy in pancreatic cancer is dosimetrically feasible with shorter treatment times, fewer MUs delivered, and comparable CIs for VMAT when compared with IMRT.
Copyright © 2014 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D-CRT; IMRT; Pancreas; VMAT

Mesh:

Year:  2014        PMID: 24857696     DOI: 10.1016/j.meddos.2014.04.001

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  5 in total

1.  Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy.

Authors:  Nurten Bahtiyar; İlhan Onaran; Birsen Aydemir; Onur Baykara; Selmin Toplan; Fulya Yaman Agaoglu; Mehmet Can Akyolcu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

2.  Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy.

Authors:  Feng Teng; Lingling Meng; Fuhai Zhu; Gang Ren
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Authors:  Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-06-12       Impact factor: 3.621

4.  Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis.

Authors:  Vijay P Raturi; Taku Tochinai; Hidehiro Hojo; Toshiya Rachi; Kenji Hotta; Naoki Nakamura; Sadamoto Zenda; Atsushi Motegi; Takaki Ariji; Yasuhiro Hirano; Hiromi Baba; Hajime Ohyoshi; Masaki Nakamura; Masayuki Okumura; Yanping Bei; Tetsuo Akimoto
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

5.  Automated treatment planning as a dose escalation strategy for stereotactic radiation therapy in pancreatic cancer.

Authors:  Savino Cilla; Anna Ianiro; Carmela Romano; Francesco Deodato; Gabriella Macchia; Pietro Viola; Milly Buwenge; Silvia Cammelli; Antonio Pierro; Vincenzo Valentini; Alessio G Morganti
Journal:  J Appl Clin Med Phys       Date:  2020-10-16       Impact factor: 2.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.